Loading
A phase 2 trial of retlirafusp alfa, nab-paclitaxel and fluzoparib in triple-negative breast cancer, run by Harbin Medical University, not yet recruiting.
Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer is a phase 2, interventional study registered as NCT07752550 by Harbin Medical University, with a registry enrolment figure of 120 participants, started 2026-07-30 and due to reach its primary completion in 2028-07-30. Interventions recorded: Retlirafusp alfa+Nab-paclitaxel:; Retlirafusp alfa+Fluzoparib; Retlirafusp alfa+TP-AC; Retlirafusp alfa+Fluzoparib. Conditions listed: Triple-Negative Breast Cancer (TNBC). Triple-negative eligibility wording from the registry: "Histopathologically confirmed recurrent or metastatic triple-negative breast cancer, defined as ER-negative (IHC ER-positive percentage \<1%), PR-negative (IHC PR-positive percentage \<1%), and HER2-negative (IHC -/+ or IHC ++ but FISH/CISH -);". Sites: China. No results are recorded here; the registry entry is the source.
Shares Nab-paclitaxel, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Nab-paclitaxel, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Nab-paclitaxel, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Nab-paclitaxel, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Nab-paclitaxel, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Nab-paclitaxel, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Nab-paclitaxel, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Nab-paclitaxel, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.